Abstract
Accumulating evidence indicates that regulatory T cells (Treg) are a distinct group of immune cells that are essential in maintaining immunologic homeostasis, largely by their ability to suppress responses mediated by other populations of immune cells. In a microbial infection, this suppressive function can be temporally overridden via different mechanisms so that the immune system can mount efficient antimicrobial immunity. However, if Tregs suppressive function is not restored after the elimination of pathogens, the resulting immune hyperactivity would injure self tissues and autoimmune diseases may occur. In case of cancer, the overexpressed self-antigens can induce tumor/self-specific Treg cells that suppress effective antitumor responses. A wealth of evidence clearly shows that some microbes and their products, such as CpG-ODN, OK-432 and BCG, are effective in cancer treatment, most likely by suppression of Tregs function. Therefore, the search for approaches which can override Tregs suppressive functions and trigger an efficient antitumor immunity is crucial to the development of effective cancer immunotherapy.
Current Cancer Therapy Reviews
Title: Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Volume: 6 Issue: 1
Author(s): Xinhai Zhang, Rick F. Thorne, Thomas E. Wagner and Yanzhang Wei
Affiliation:
Abstract: Accumulating evidence indicates that regulatory T cells (Treg) are a distinct group of immune cells that are essential in maintaining immunologic homeostasis, largely by their ability to suppress responses mediated by other populations of immune cells. In a microbial infection, this suppressive function can be temporally overridden via different mechanisms so that the immune system can mount efficient antimicrobial immunity. However, if Tregs suppressive function is not restored after the elimination of pathogens, the resulting immune hyperactivity would injure self tissues and autoimmune diseases may occur. In case of cancer, the overexpressed self-antigens can induce tumor/self-specific Treg cells that suppress effective antitumor responses. A wealth of evidence clearly shows that some microbes and their products, such as CpG-ODN, OK-432 and BCG, are effective in cancer treatment, most likely by suppression of Tregs function. Therefore, the search for approaches which can override Tregs suppressive functions and trigger an efficient antitumor immunity is crucial to the development of effective cancer immunotherapy.
Export Options
About this article
Cite this article as:
Zhang Xinhai, Thorne F. Rick, Wagner E. Thomas and Wei Yanzhang, Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope, Current Cancer Therapy Reviews 2010; 6 (1) . https://dx.doi.org/10.2174/157339410790596470
DOI https://dx.doi.org/10.2174/157339410790596470 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy
Letters in Drug Design & Discovery Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants (ASIA) – Animal Models as a Proof of Concept
Current Medicinal Chemistry Boosting Interleukin-10 Production: Therapeutic Effects and Mechanisms
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry Clinical Pharmacogenetics of Methotrexate
Current Drug Metabolism Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges
Current Drug Discovery Technologies ImmunemiR - A Database of Prioritized Immune miRNA Disease Associations and its Interactome
MicroRNA Endothelial Progenitor Cells as Mediators of the Crosstalk between Vascular Repair and Immunity: Lessons from Systemic Autoimmune Diseases
Current Medicinal Chemistry Autoantibodies in Autoimmune Diseases
Current Pharmaceutical Design Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design Therapeutic Monoclonal Antibodies and Multiple Sclerosis: The Essentials
Medicinal Chemistry New Immunosuppressants: Immunosuppression and Immunomodulation
Medicinal Chemistry Reviews - Online (Discontinued) Approaches to the Pharmacological Modulation of Plasmacytoid Dendritic Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) The Role of STATs in Inflammation and Inflammatory Diseases
Current Pharmaceutical Design Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design Immunology of VIP: A Review and Therapeutical Perspectives
Current Pharmaceutical Design